Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial.
Journal of Clinical Oncology.
Times cited: 79
RC0639: Phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Breast Cancer Research and Treatment.
Times cited: 12